82VS

Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertise in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment further demonstrating our philosophy that investments in companies should positively impact the health and well-being of patients. Main areas of scientific interest Forbion contributes to the health and well-being of patients worldwide. Our companies have positively affected almost half a million patients in the areas of: Life Sciences Autoimmune & Inflammation Cardiovascular/Metabolic Central nervous system Digestive & Renal Oncology Ophthamology Orphan/rare disease Respiratory BioEconomy Food Agriculture Materials Environmental Technologies Forbion then and now Forbion was born out of ABN AMRO Capital Life Sciences. Today, to emphasize its value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits. Forbion currently manages €3 bn across nine funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees. Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility. € 3bn across 9 funds € 750m Forbion Ventures VI € 600m Forbion Growth Opportunities Fund II 43 active portfolio companies

Amgen Ventures has made >70 INVESTMENTS placing >$400M of the $625M Amgen has committed to support healthcare innovation and interconnectivity at all stages. Amgen Ventures offers us a unique conduit to identify and support key innovators in healthcare at early stages of translational sciences by providing investment capital and access to Amgen’s vast experience in developing leading drugs. AREAS OF INVESTMENTTHERAPEUTICS: Identify promising pipeline assets in Amgen’s therapeutic areas: oncology, immune- oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. DRUG DISCOVERY & EMERGING TECHNOLOGIES: Improve the discovery process with new technologies including cell therapies, gene-editing and gene-therapies, regenerative medicine, and drug delivery. DIGITAL HEALTHCARE SERVICES, INFORMATION & ANALYTICS: Enhance Amgen medicines by improving real world outcomes and delivering greater value to healthcare systems, doctors, and patients.

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

At Pappas Capital, we are dedicated to furthering life science discoveries and bringing groundbreaking solutions to market. Pappas Capital is laser focused on the life science sector. For more than 28 years we have been investing in and building innovative companies that are developing the next generation of life science products and technologies. We’ve invested in more than 85 companies across the United States and Canada – in fields that span the range of human disease. The products our companies have brought to market – for treating such conditions as melanoma, ovarian cancer, and hemophilia, to name a few – have been used throughout the world to treat tens of thousands of patients and account for billions of dollars of revenue. Whether you’re looking for capital or have capital to invest, contact us and learn how we can put our expertise to work for you.

K2HV’s investment professionals bring together substantial experience across multiple verticals in healthcare finance and operations, as well as considerable scientific knowledge. Our diverse backgrounds and experience give us a deep understanding of the needs of innovative healthcare companies throughout their lifecycles, and underpin our innovative and creative approach to investing. Our leadership team has committed more than $4 billion to over 100 private and public companies in the life sciences and healthcare industries. High Impact Investments, Long-Term ViewUniquely flexible, permanent capital structure enables us to provide long-term financing solutions and meet the evolving capital needs of growing companies Broad investment mandate allows us to be creative with financing structures Primary focus on customized debt financings, but able to invest in equity as well

SCI Ventures is a novel, evergreen fund created to catalyze innovative cures for paralysis. Backed by the leading foundations for spinal cord injury in the US and Europe, and advised by world-class neuroscientists, we invest in early-stage companies developing cure-oriented therapies for spinal cord injury and other related markets. We invest globally in companies with the greatest potential to impact our mission, typically at the Seed and Series A stages. We follow a venture philanthropy model, inspired by successful initiatives in other disease areas, to catalyze an investment market aimed at reversing paralysis. We focus on investing in companies advancing cures for paralysis-related challenges, prioritizing both long-term neural pathway restoration and immediate clinical impact. Our investments are guided by community priorities and scientific rigor, leveraging our team's expertise and the support of research foundations. A new wave of innovation For the first time, the combination of breakthroughs in biology, engineering and computing make a cure to paralysis a real possibility. An evergreen fund that redeploys 100% of its returns Venture philanthropy has been adopted by a number of disease- focused organisations, including JDRF’s T1D Fund and the Cystic Fibrosis Foundation, to deploy their own capital to produce a tangible impact and to attract the traditional life-science venture capital industry to their cause. SCI Ventures is making investments with the intent of generating a financial return. All returns will be recycled and reinvested within the fund to take more targeted shots at the goal of curing paralysis. All initial operating costs of SCI Ventures are being met by the Christopher and Dana Reeve Foundation, allowing all donated capital to be invested in cutting-edge, early-stage companies. Investment strategy Catalyzing an investment market to address spinal cord repair. Recent advances in science and technology have made recovery from paralysis a real possibility. We target near-term functional improvement, while also backing the ultimate goal of biological repair of the spinal cord. Our strategy is guided by the priorities of those living with a spinal cord injury. We focus on curative therapies for motor and sensory deficits and leave the important work of care and adaptation to others. SCI Ventures is uniquely positioned to de-risk assets for a broad range of adjacent neurological conditions. We invest in technologies targeted at SCI. There are many similarities between SCI and other conditions including stroke, neurodegenerative diseases or neural circuit disorders such as epilepsy or pain. The technologies we back have the potential to yield high impact beyond the SCI community. We use strict criteria to assess a company’s investment impact, focusing on prospective financial return. We aim to make an impact, by identifying the most innovative technologies and supporting at an early stage the most entrepreneurial management teams, regardless of where they are in the world. We assess each company for its scientific maturity and potential for clinical impact.